Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures

Apostolova, 2011, Mitochondrial toxicity in HAART: an overview of in vitro evidence, Curr. Pharm. Des., 17, 2130, 10.2174/138161211796904731 Birkus, 2002, Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors, Antimicrob. Agents Chemother., 46, 716, 10.1128/AAC.46.3.716-723.2002 Callebaut, 2015, In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate, Antimicrob. Agents Chemother., 59, 5909, 10.1128/AAC.01152-15 Callebaut, 2017, In vitro sensitivity of primary osteoblasts to tenofovir alafenamide: lack of effect at clinically relevant drug concentrations, PLoS One, 10.1371/journal.pone.0169948 Carr, 2003, Toxicity of antiretroviral therapy and implications for drug development, Nat. Rev. Drug Discov., 2, 624, 10.1038/nrd1151 Durand-Gasselin, 2009, Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys, Mol. Pharm., 6, 1145, 10.1021/mp900036s Gaur, 2016, Safety and efficacy of E/C/F/TAF in HIV-1 infected treatment-naïve adolescents Hawkins, 2005, Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens, J. Acquir. Immune Defic. Syndr., 39, 406, 10.1097/01.qai.0000167155.44980.e8 Hawkins, 2011, Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients, Antimicrob. Agents Chemother., 55, 1549, 10.1128/AAC.00910-10 Höschele, 2006, Cell culture models for the investigation of NRTIinduced mitochondrial toxicity. Relevance for the prediction of clinical toxicity, Toxicol. In Vitro, 20, 535, 10.1016/j.tiv.2005.11.007 Johnson, 2001, Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase, J. Biol. Chem., 276, 40847, 10.1074/jbc.M106743200 Kiser, 2008, Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients, J. Acquir. Immune Defic. Syndr., 47, 298, 10.1097/QAI.0b013e31815e7478 Kohler, 2007, A brief overview of mechanisms of mitochondrial toxicity from NRTIs, Environ. Mol. Mutagen, 48, 166, 10.1002/em.20223 Lee, 2005, Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue, Antimicrob. Agents Chemother., 49, 1898, 10.1128/AAC.49.5.1898-1906.2005 Lewis, 2001, Mitochondrial DNA depletion, oxidative stress and mutation: mechanisms of nucleoside reverse transcriptase inhibitor toxicity, Lab. Invest., 81, 777, 10.1038/labinvest.3780288 Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method, Methods, 25, 402, 10.1006/meth.2001.1262 Lund, 2007, Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs, Antimicrob. Agents Chemother., 51, 2531, 10.1128/AAC.00039-07 Mills, 2015, Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized Phase 2 study, J. Acquir. Immune Defic. Syndr., 69, 439, 10.1097/QAI.0000000000000618 Moyle, 2000, Clinical manifestations and management of antiretroviral nucleoside analog related mitochondrial toxicity, Clin. Ther., 22, 911, 10.1016/S0149-2918(00)80064-8 Pan-Zhou, 2000, Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells, Antimicrob. Agents Chemother., 44, 496, 10.1128/AAC.44.3.496-503.2000 Panel on Antiretroviral Guidelines for Adult and Adolescents, 2016 Pozniak, 2016, Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label Phase 3 study, J. Acquir. Immune Defic. Syndr., 71, 530, 10.1097/QAI.0000000000000908 Pruvost, 2005, Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients, Antimicrob. Agents Chemother., 49, 1907, 10.1128/AAC.49.5.1907-1914.2005 Pruvost, 2009, Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir, Antimicrob. Agents Chemother., 53, 1937, 10.1128/AAC.01064-08 Ray, 2016, Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus, Antivir. Res., 125, 63, 10.1016/j.antiviral.2015.11.009 Ruane, 2013, Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults, J. Acquir. Immune Defic. Syndr., 63, 449, 10.1097/QAI.0b013e3182965d45 Sax, 2014, Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study, J. Acquir. Immune Defic. Syndr., 67, 52, 10.1097/QAI.0000000000000225 Sax, 2015, Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials, Lancet, 38, 2606, 10.1016/S0140-6736(15)60616-X Seifert, 2016, Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady-state, AIDS Res. Hum. Retroviruses, 32, 981, 10.1089/aid.2016.0008 Venhoff, 2007, Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors, Antivir. Ther., 12, 1075, 10.1177/135965350701200704 Wohl, 2016, Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results, J. Acquir. Immune Defic. Syndr., 72, 58, 10.1097/QAI.0000000000000940